Rhythm Pharmaceuticals EPS beats by $0.02

Rhythm Pharmaceuticals (NASDAQ:RYTM): Q1 GAAP EPS of -$0.78 beats by $0.02.

Cash, cash equivalents and short-term investments of $257.4M

Press Release

https://seekingalpha.com/news/3568190-rhythm-pharmaceuticals-eps-beats-0_02

PetMed Express EPS beats by $0.06, beats on revenue

PetMed Express (NASDAQ:PETS): Q4 GAAP EPS of $0.35 beats by $0.06.

Revenue of $74.29M (+15.1% Y/Y) beats by $8.05M.

Press Release

https://seekingalpha.com/news/3568173-petmed-express-eps-beats-0_06-beats-on-revenue

Stemline up on acquisition bid

Privately held Menarini Group has agreed to acquire Stemline Therapeutics (NASDAQ:STML) for $12.50 per share, consisting of $11.50 in cash plus one contingent value right (CVR) that will pay $1.00 in cash upon the completion of the first sale of Elzonris (tagraxofusp) in any EU5 country (UK, France, Spain, Germany, Italy) after European Commission approval.

The transaction, financed with cash on hand, should close this quarter.

Friday’s close was $4.75.

https://seekingalpha.com/account/portfolio

NanoViricides up on COVID-19 plan

NanoViricides (NYSEMKT:NNVC) has signed a Confidential Disclosure Agreement (“CDA”) with a pharmaceutical company in the Asian region to explore collaborating on the Company’s COVID-19 program.

The Company has already identified certain drug candidates that are active against multiple coronaviruses in cell culture studies.

NanoViricides intends to perform animal studies for the clinical SARS-CoV-2 nanoviricide drug candidate for developing information for entering into first-in-human studies under the FDA or other regulatory agencies.

https://seekingalpha.com/news/3568165-nanoviricides-up-9-premarket-on-covidminus-19-plan

Vir and Alnylam identify inhalable drug candidate for COVID-19

Vir Biotechnology (NASDAQ:VIR) and collaboration partner Alnylam Pharmaceuticals (NASDAQ:ALNY) announce a new COVID-19 candidate, VIR-2703, an inhalable RNAi therapeutic that targets the SARS-CoV-2 genome for the potential treatment and/or prevention of the respiratory illness.

VIR-2703 has predicted reactivity against more that 99.9% of the 4,300+ SARS-CoV-2 genomes currently available in public databases, including the SARS-CoV genome from the 2003 SARS outbreak.

The companies intend to meet with the FDA to discuss an accelerated path to clinical trials.

https://seekingalpha.com/news/3568167-vir-and-alnylam-identify-inhalable-drug-candidate-for-covidminus-19

Anixa Bio up on discovery of first COVID-19 candidate

Anixa Biosciences (NASDAQ:ANIX), together with partner OntoChem GmbH, has identified its first therapeutic candidate against COVID-19 and has advanced the compound into biological testing.

The compound works by disrupting the interaction of the virus’s endoribonuclease with a host human protein that is necessary for the virus to replicate upon infection.

https://seekingalpha.com/news/3568129-anixa-bio-up-62-premarket-on-discovery-of-first-covidminus-19-candidate

Applied DNA Sciences up on encouraging COVID-19 vaccine data

Nano cap Applied DNA Sciences (NASDAQ:APDN) and COVID-19 vaccine development partner Takis Biotech announce that the first injections of their DNA vaccine candidates against the SARS-CoV-2 spike protein produced neutralizing antibodies in test animals in work performed in Italy.

Linear DNA dose-response studies will start this week.

https://seekingalpha.com/news/3568107-applied-dna-sciences-up-24-premarket-on-encouraging-covidminus-19-vaccine-data